Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

25,524 signal articles · 27 in last 24h · 122,292 total before filter · latest 3h ago
27last 24h
1253last 7d
210● bullish (7d)
151● bearish (7d)
205publishers
AllMacro211Earnings430M&A97Regulatory24Product9Analyst11
Sentiment:bullishneutralbearishshow all (incl. clickbait)
California sends Tesla a message with its new EV rebate
TheStreet38d agoneutral
California sends Tesla a message with its new EV rebate

Every incentive comes with a message. There's the money, the part that shows up in your bank account. And there's the meaning underneath it, the quiet signal about who a government wants to help and who it would rather push to the back of the line. Electric vehicles have had a rough year. ...

Morgan Stanley Q2 Earnings Call Highlights
MarketBeat38d agoneutral
Morgan Stanley Q2 Earnings Call Highlights

Morgan Stanley (NYSE:MS) reported record second-quarter 2026 results, with executives citing strong client activity across institutional securities, wealth management and investment management, as well as continued benefits from the firm’s integrated business model. Chairman and Chief Executive Off

Johnson & Johnson Q2 Earnings Call Highlights
MarketBeat38d agoneutral
Johnson & Johnson Q2 Earnings Call Highlights

Johnson & Johnson (NYSE:JNJ) raised its full-year 2026 outlook after reporting second-quarter sales growth that management said was supported by strength in Innovative Medicine, new product launches and a broad portfolio that helped offset continued pressure from STELARA biosimilar competition.

Morgan Stanley Mulls Acquisitions
The Wall Street Journal38d agoneutral
Morgan Stanley Mulls Acquisitions

Morgan Stanley is mulling using its pile of excess capital for acquisitions. “Are we seeing opportunities come across the transom that are interesting? We are. Are we potentially looking at stuff that could bolt on to the strategy? We are, but I would tell you right now, the bias continues to be to go organic,” said CEO Ted Pick, referring to organically growing the firm, during a call with analysts.

Morgan Stanley’s Wealth Division Got a Boost From Big IPOs, Too
The Wall Street Journal38d agoneutral
Morgan Stanley’s Wealth Division Got a Boost From Big IPOs, Too

The historic SpaceX initial public offering was good for Morgan Stanley’s investment banking division. The firm’s wealth division also got a boost from IPOs. Morgan Stanley’s wealth division raked in $148 billion in net new assets in the second quarter, over half of which the firm said was related to IPOs of companies that use the firm’s workplace investing platform.

Markets Have Passed Their First Earnings Test, Now Comes Tech
Barrons.com38d agoneutral
Markets Have Passed Their First Earnings Test, Now Comes Tech

U.S. stocks caught a break this week—and found a window in which to exploit it over the next two weeks—as inflation data suggest a taming of Federal Reserve rate-hike bets and the outlook from a key player in the market for artificial intelligence outpaced Wall Street’s forecasts. Tuesday’s inflation data got the ball rolling, with the softest monthly print since the Covid-19 pandemic and annual gains that fell shy of Wall Street estimates cratering bets on a July Fed rate hike.

Stripe and Private-Equity Firm Advent Offer to Buy PayPal
The Wall Street Journal38d agobullish
Stripe and Private-Equity Firm Advent Offer to Buy PayPal

Stripe and buyout firm Advent International made a joint takeover bid for PayPal Holdings in a deal that would value the fintech company at around $53 billion, according to people familiar with the matter. Stripe and Advent proposed paying $60.50 a share for PayPal, the people said. There are no guarantees PayPal will be receptive, the people added.

Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval
Reuters38d agobearish
Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval

July 15 () - Shares of Celcuity fell about 8% in premarket trading on Wednesday, as the delayed commercial launch ‌of its newly approved breast cancer drug and treatment-tolerability ‌concerns overshadowed the company's first U. Food and Drug Administration on ​Tuesday approved gedatolisib, branded as Revtorpyk, for certain patients with advanced breast cancer whose tumors do not carry a PIK3CA mutation.

BlackRock Q2 Earnings Call Highlights
MarketBeat38d agoneutral
BlackRock Q2 Earnings Call Highlights

BlackRock (NYSE:BLK) executives said the asset manager delivered record second-quarter results and its strongest first half on record, driven by broad-based client inflows, higher markets, acquisitions and continued demand for ETFs, private markets and technology offerings. Chief Financial Officer

ASML Just Raised Guidance Again — Is This the Strongest AI Stock Story Nobody’s Talking About?
24/7 Wall St.38d agoneutral
ASML Just Raised Guidance Again — Is This the Strongest AI Stock Story Nobody’s Talking About?

The AI investment boom has created a sharp divide between companies benefiting from long-term demand and those merely riding short-term enthusiasm. While many technology businesses continue spending hundreds of billions of dollars on AI infrastructure, investors have increasingly questioned whether those investments will eventually slow. Yet every quarter seems to produce another reminder that the ... ASML Just Raised Guidance Again — Is This the Strongest AI Stock Story Nobody’s Talking About?

Why Elevance Earnings Gave Health Insurance Stocks A Cold; UNH Up Next
Investor's Business Daily38d agoneutral
Why Elevance Earnings Gave Health Insurance Stocks A Cold; UNH Up Next

Elevance Health topped Q2 earnings estimates Wednesday, despite falling medical membership, but profit was boosted by one-time "below-the-line" factors and the full-year outlook was underwhelming. ELV stock tumbled, making it among the S&P 500's early laggards. Molina Healthcare, another S&P 500 managed care stock, joined Elevance among the biggest laggards performers in pre-market trading.

Stock Futures Rise on Cooler Producer Inflation
Barrons.com38d agoneutral
Stock Futures Rise on Cooler Producer Inflation

A cooler-than-expected PPI print helped solidify stock futures' climb into the green. Nasdaq futures led, up 0.6%. S&P 500 futures and Dow futures both rose 0.2%. June's producer price index came in at 5.